Summary

In collaboration with researchers at Harvard Medical School, Baylor College of Medicine, Christ Hospital, and the HCA Research Institute, Surgisphere is pleased to announce the publication of a study on cardiovascular disease, drug therapy, and mortality in coronavirus disease 2019 (Covid-19) patients.

This study confirms the association between various cardiovascular risk factors and mortality, finding that the presence of coronary artery disease, congestive heart failure, and arrhythmia are independent predictors of in-hospital death. COPD, smoking, and age over 65 years are also associated with an increased risk of mortality, while female gender is predictive of survival.

One of the most important contributions of this study is the finding that the use of either ACE inhibitors or statins is associated with improved survival in Covid-19 patients. This does not mean that ACE inhibitors or statins should be started de novo in Covid-19 patients, a question that would best be answered by a randomized controlled trial. Interested readers are invited to review the full article, now live at the New England Journal of Medicine.

This is one of several recent publications by Surgisphere. Our other ongoing work includes determining the impact of paclitaxel devices on survival for patients with peripheral vascular disease (presented at an FDA / AdvaMed forum in April), the impact of drug eluting stents and atherectomy on limb salvage (published in the Annals of Vascular Surgery), and various invited presentations on healthcare economics, healthcare quality, machine learning, and clinical care.

Highlights

Cardiovascular disease is predictive of mortality in Covid-19 patients in one of the largest sample size studies published to date.
ACE inhibitors, ARBs, and statins are not predictive of mortality in these patients, based off a multivariable logistic regression analysis.
Read the Full Article

Mehra MR, Desai SS, Kuy S, Henry TD, and Patel AN. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. NEJM 2020 May 1.

Technology

This study was made possible through Surgisphere’s award winning cloud based healthcare data analytics platform, QuartzClinical, which was ranked #1 by Frost and Sullivan for its machine learning-powered data analytics in 2019. Data used for the study came from 8,910 Covid-19 patients from 169 hospitals on three continents.

Surgisphere’s data analytics system is used by healthcare institutions around the world to improve how they deliver high value healthcare. Through real time insight into clinical, quality, supply chain, and financial performance, hospitals and physician practices are able to achieve higher quality healthcare for a more affordable cost.

Surgisphere is an ISO 27001:2013 certified public service company based in Chicago, Illinois. As a physician-led organization, Surgisphere is dedicated to improving the health of patients using a more effective data driven approach.

Next Generation Informatics

Surgisphere’s platform helps hospitals improve interoperability between clinical, quality, supply chain, and financial systems to obtain unparalleled insight into business operations. Dynamic dashboards, detailed benchmarks, and natively integrated lean six sigma and project management tools are used to create real time insights into patient care. Learn more about our award winning and internationally recognized platform at https://www.QuartzClinical.com.

  • Learn more about who we are and our values here: About Us
  • See some of our success stories here: Case Studies